PLA2G7 and Alzheimer disease: Preliminary clinical evidence that targeting Lp-PLA2 may provide a novel treatment to slow the progression of AD comes from a phase 2a study with a non-central nervous system (CNS)-penetrant Lp-PLA2 inhibitor rilapladib, which demonstrated improved cognitive outcomes and changes to a number of mechanism- and disease-related biomarkers [4].